Condition
Endocrine Breast Diseases
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Unknown2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03939156Unknown
Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer
NCT01499160Phase 2Terminated
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
NCT03373708Phase 2Unknown
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Showing all 3 trials